ArticleExperimental and therapeutic medicine2025
Enhanced SLC2A4 expression mitigates insulin resistance in gestational diabetes mellitus via the FoxO signaling pathway
Article in Experimental and therapeutic medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gestational diabetes mellitus (GDM), a type of diabetes mellitus occurring in pregnant women, increases the risk of birth trauma. Solute carrier family 2 member 4 (SLC2A4) polymorphism is notably associated with GDM susceptibility; however, the mechanism is unknown. In the present study, HTR-8/SVneo cells were treated with high glucose concentrations and transfected with SLC2A4 and Forkhead box O (FoxO)1 to investigate their roles in the insulin (INS) resistance of GDM trophoblast cells. The results showed that the expression levels of SLC2A4, INS receptor (INSR) and INS were significantly decreased in HTR-8/SVneo cells under hyperglycemic conditions. Furthermore, overexpression of SLC2A4 reduced the levels of phosphorylated FoxO (p-FoxO)1, FoxO1, p-FoxO3a and FoxO3a but enhanced the expression levels of INS and INSR, improving glucose uptake within the hyperglycemic environment. Additionally, both the analysis of the signaling pathways related to SLC2A4 and GDM using the Kyoto Encyclopedia of Genes and Genomes pathway analysis and the results of CCK-8 determination of cell vitality both emphasized that the FoxO signaling was a pivotal pathway affected by SLC2A4 in GDM. In conclusion, the present study demonstrated that overexpression of SLC2A4 enhanced the INS signaling pathway, as evidenced by western blotting showing increased levels of INSR and INS, along with elevated glucose uptake. Concurrently, SLC2A4 overexpression inhibited the FoxO signaling pathway, as indicated by reduced protein levels of p-FoxO1, total FoxO1, p-FoxO3a and total FoxO3a. Collectively, these molecular alterations contribute to the alleviation of insulin resistance in patients with GDM.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.